Thromboembolic risk assessment in a phenotypically cured factor-V-Leiden carrier after orthotopic liver transplantation

Clinical Laboratory

Volumn 56, Issue 5-6, 2010, Pages 245-247

  Strobel, Julian ^a   Ringwald, Juergen ^a   Zimmermann, Robert ^a   Eckstein, Reinhold ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Factor V Leiden; Liver transplantation; Thrombembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; ARTICLE; CASE REPORT; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HUMAN; LIVER TRANSPLANTATION; MALE; PHENOTYPE; RISK ASSESSMENT; THROMBOEMBOLISM;

ALANINE TRANSAMINASE; ANTICOAGULANTS; ASPARTATE AMINOTRANSFERASES; CARRIER STATE; FACTOR V; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHENOTYPE; PHENPROCOUMON; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM;

EID: 77953299536     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-4.
2. Segers K, Dahlbäck B, Nicolaes GAF. Coagulation factor V and thrombophilia: Background and mechanisms. Thromb Haemost 2007;98:530-42.
3. Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001;86:395-403.
4. Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007;92:1107-14.
5. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998;92:3035-41.
6. Loew A, Jacob D, Neuhaus P, Riess H. Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation. Transplantation 2005;79:1422-7.
7. Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998;42:744-9.
8. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008;112:19-27.
9. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:401-28.
10. Biesma DH, de Man RA, Nieuwenhuis HK, Haas FJ. Recurrent venous thrombosis despite correction of activated protein C resistance following orthotopic liver transplantation. Thromb Haemost 1998;80:525-6.
11. Tracy PB, Eide LL, Bowie EJ, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood 1982;60:59-63.
12. Nesheim ME, Nichols WL, Cole TL, et al. Isolation and study of an acquired inhibitor of human coagulation factor V. Journal of Clinical Investigation 1986;77:405-15.
13. Giampaolo A, Vulcano F, Macioce G, et al. Factor-V expression in platelets from human megakaryocyte culture. Br J Haematol 2004;128:108-11.
14. Gould WR, Simioni P, Silveira JR, Tormene D, Kalafatis M, Tracy PB. Megakaryocytes endocytose and subsequently modify human factor V in vivo to form the entire pool of a unique platelet-derived cofactor. J Thromb Haemost 2005;3:450-6.
15. Suehiro Y, Veljkovic DK, Fuller N, et al. Endocytosis and storage of plasma factor V by human megakaryocytes. Thromb Haemost. 2005;94:585-92.